WHO Guideline on the Use of GLP-1 Therapies for the Treatment of Obesity in Adults (2025)

GLP-1 Receptor Agonists: Cardiovascular, Mortality, and Kidney Outcomes — Systematic Review and Meta-Analysis (Lancet 2021)

SELECT Trial — Semaglutide 2.4 mg Cuts CV Events 20% (NEJM 2023)

STEP UP Trial: Semaglutide 7.2mg Achieves 20.7% Mean Weight Loss Over 72 Weeks

2026